MOIR-ACTOME presents Novo Nordisk as a company interested in its activities, specifically in WP3 which includes research objectives with non-diabetic obese patients with renal damage before and after treatment. Novo Nordisk has already participated in financing activities of the MOIR2 consortium and the LIPOBETA group of URJC, including sponsorship of the symposium "Diabetes and Obesity in Renal Disease, an update," organized by the Diabesity group of ERAEDTA and the LIPOBETA group in 2019.

MOIR-ACTOME will also have the participation of the biotechnology-based company Campo y Tierra del Jerte S.A., created in 2005 and a leader in the production and export of agricultural products such as cherries and apricots. This biocompany is interested in providing R&D technology to the field. Currently, it collaborates with A. García (METABOALL) and various universities in Spain and Chile in the development of techniques to maximize production yield and improve post-production processes.

MOIR-ACTOME will have the participation of the Association for the Fight Against Kidney Diseases - ALCER Madrid, a Madrid-based association of kidney patients. ALCER Madrid has aimed since its foundation to improve the quality of life of patients on dialysis awaiting a kidney transplant. To make this intervention possible, organ donors are necessary. To achieve this, the Association in the Community of Madrid and throughout Spain began awareness campaigns, being pioneers in this type of action. ALCER Madrid was declared of Public Utility by the City Council of Madrid on October 15, 2004, and Declared of Public Utility by the Ministry. The consortium MOIR-ACTOME has contacted them for the possibility of their participation as a non-profit association and to begin a close collaboration with patients with chronic kidney disease associated with obesity and type 2 diabetes, as well as to inform them about the research conducted by the consortium in this area.

Dr. Cristina Rondinone is the founder and CEO of the company Pep2Tango Therapeutics, whose mission is the design and preclinical studies of new triagonist peptides of incretin receptors with potential efficacy against obesity and metabolic liver disease. HEPIR has signed an agreement with Pep2Tango Therapeutics and is conducting treatments in obese mice with some of these peptides. It is worth noting that Dr. Rondinone has participated as a collaborator/observer/advisor in the two previous MOIR consortia.